Kazia Therapeutics (KZIA) Competitors $3.30 -0.24 (-6.77%) Closing price 04/17/2025 03:59 PM EasternExtended Trading$3.26 -0.04 (-1.21%) As of 04/17/2025 05:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock KZIA vs. LSB, SNYR, ABP, CING, MIRA, GOVX, NRSN, GLYC, IPA, and LPTXShould you be buying Kazia Therapeutics stock or one of its competitors? The main competitors of Kazia Therapeutics include Lakeshore Biopharma (LSB), Synergy CHC Corp. (Uplisting) (SNYR), Abpro (ABP), Cingulate (CING), MIRA Pharmaceuticals (MIRA), GeoVax Labs (GOVX), NeuroSense Therapeutics (NRSN), GlycoMimetics (GLYC), ImmunoPrecise Antibodies (IPA), and Leap Therapeutics (LPTX). These companies are all part of the "pharmaceutical products" industry. Kazia Therapeutics vs. Lakeshore Biopharma Synergy CHC Corp. (Uplisting) Abpro Cingulate MIRA Pharmaceuticals GeoVax Labs NeuroSense Therapeutics GlycoMimetics ImmunoPrecise Antibodies Leap Therapeutics Kazia Therapeutics (NASDAQ:KZIA) and Lakeshore Biopharma (NASDAQ:LSB) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, profitability, community ranking, dividends, institutional ownership, risk and earnings. Does the MarketBeat Community prefer KZIA or LSB? Kazia Therapeutics received 80 more outperform votes than Lakeshore Biopharma when rated by MarketBeat users. CompanyUnderperformOutperformKazia TherapeuticsOutperform Votes8052.98% Underperform Votes7147.02% Lakeshore BiopharmaN/AN/A Is KZIA or LSB more profitable? Company Net Margins Return on Equity Return on Assets Kazia TherapeuticsN/A N/A N/A Lakeshore Biopharma N/A N/A N/A Which has more risk & volatility, KZIA or LSB? Kazia Therapeutics has a beta of 2.28, suggesting that its stock price is 128% more volatile than the S&P 500. Comparatively, Lakeshore Biopharma has a beta of 0.58, suggesting that its stock price is 42% less volatile than the S&P 500. Do analysts rate KZIA or LSB? Kazia Therapeutics presently has a consensus target price of $11.50, suggesting a potential upside of 248.48%. Given Kazia Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Kazia Therapeutics is more favorable than Lakeshore Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kazia Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Lakeshore Biopharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has better valuation & earnings, KZIA or LSB? Kazia Therapeutics has higher earnings, but lower revenue than Lakeshore Biopharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKazia Therapeutics$2.31M1.44-$17.56MN/AN/ALakeshore Biopharma$672.27M0.02-$61.09MN/AN/A Does the media refer more to KZIA or LSB? In the previous week, Kazia Therapeutics had 3 more articles in the media than Lakeshore Biopharma. MarketBeat recorded 5 mentions for Kazia Therapeutics and 2 mentions for Lakeshore Biopharma. Kazia Therapeutics' average media sentiment score of 0.20 beat Lakeshore Biopharma's score of -0.50 indicating that Kazia Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kazia Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Lakeshore Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative Do insiders and institutionals have more ownership in KZIA or LSB? 30.9% of Kazia Therapeutics shares are held by institutional investors. Comparatively, 52.6% of Lakeshore Biopharma shares are held by institutional investors. 1.0% of Kazia Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. SummaryKazia Therapeutics beats Lakeshore Biopharma on 10 of the 12 factors compared between the two stocks. Get Kazia Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KZIA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KZIA vs. The Competition Export to ExcelMetricKazia TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.32M$6.44B$5.30B$7.35BDividend YieldN/A3.20%5.45%4.30%P/E RatioN/A6.8921.8617.81Price / Sales1.44230.51380.6697.70Price / CashN/A65.6738.2634.64Price / Book-1.685.936.453.98Net Income-$17.56M$142.99M$3.22B$247.81M1 Month Performance244.47%-13.56%-9.76%-7.94%1 Year Performance-12.23%-8.89%11.49%1.52% Kazia Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KZIAKazia Therapeutics3.3196 of 5 stars$3.30-6.8%$11.50+248.5%-4.7%$3.32M$2.31M0.0012Short Interest ↓Gap DownLSBLakeshore Biopharma0.5006 of 5 stars$1.76+4.1%N/AN/A$15.73M$672.27M0.00773Short Interest ↑Gap UpSNYRSynergy CHC Corp. (Uplisting)3.0749 of 5 stars$1.79+0.4%$10.00+458.7%N/A$15.34M$34.83M0.0040Lockup ExpirationNews CoverageHigh Trading VolumeABPAbproN/A$0.30+6.9%$4.00+1,255.9%N/A$15.29M$122,000.000.0015Gap UpCINGCingulate2.09 of 5 stars$4.02+5.8%$16.00+298.0%+381.8%$15.15MN/A-0.2720Short Interest ↑Negative NewsMIRAMIRA Pharmaceuticals2.7108 of 5 stars$0.89+2.9%$14.00+1,473.0%+8.5%$14.96MN/A-1.592Short Interest ↓News CoverageGap DownGOVXGeoVax Labs2.2939 of 5 stars$1.07+4.9%$14.20+1,227.1%-45.4%$14.81M$3.95M-0.1910Analyst ForecastShort Interest ↑Analyst RevisionNews CoverageNRSNNeuroSense Therapeutics0.3711 of 5 stars$1.08+1.9%N/A-32.0%$14.76MN/A-1.6910Short Interest ↑GLYCGlycoMimetics1.7243 of 5 stars$0.22+10.0%N/A-89.7%$14.32M$10,000.000.0050Analyst ForecastNews CoverageIPAImmunoPrecise Antibodies2.6949 of 5 stars$0.46+6.0%$4.00+775.1%-64.7%$14.20M$24.00M-0.5980Short Interest ↓Gap DownLPTXLeap Therapeutics1.5415 of 5 stars$0.34+5.2%$4.92+1,341.8%-87.7%$14.07MN/A-0.1840Short Interest ↑Gap Down Related Companies and Tools Related Companies LSB Alternatives SNYR Alternatives ABP Alternatives CING Alternatives MIRA Alternatives GOVX Alternatives NRSN Alternatives GLYC Alternatives IPA Alternatives LPTX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KZIA) was last updated on 4/19/2025 by MarketBeat.com Staff From Our PartnersGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredAmazon ShockerJeff Bezos quietly backing world-changing tech (not AI) The Amazon founder is quietly advancing a radical t...Stansberry Research | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kazia Therapeutics Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Kazia Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
